Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Stomach Neoplasms 1Sarcoma, Clear Cell 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Multiple Myeloma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 3Irinotecan 3Surveys and Questionnaires 2Specimen Handling 2Radiosurgery 2Leucovorin 2Ketamine 2Hydroxychloroquine 2Fluorouracil 2Capecitabine 2ulixertinib 1tegafur-gimeracil-oteracil 1regorafenib 1pazopanib 1lanreotide 1fludarabine phosphate 1fludarabine 1dostarlimab 1dolasetron 1dexamethasone acetate 1dexamethasone 21-phosphate 1danvatirsen 1cobimetinib 1brivanib 1auricularum 1atezolizumab 1alectinib 1aldesleukin 1abelacimab 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrointestinal Neoplasms × dostarlimab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡